Thats one of the critical pieces of information provided by this paper, he said. We looked at how frequently aspirin resistance occurred in all patients and its prevalence in patients who suffered clinical aspirin failure. What we found was, across the board, about 80 percent of the patients in our study, were aspirin sensitive -- their platelets did not aggregate in arteries -- and 20 percent were aspirin resistant.
However, when we asked the same question of the data from patients who had a second stroke while on aspirin [clinical aspirin failures], 80 percent were aspirin resistant, said Gengo.
A large meta-analysis published nearly simultaneously in the online version of the British Medical Journal (BMJ) reached a similar finding. However, Gengo noted that while the BMJ paper is a very important review, the UB/DENT study provides more definitive information on the issue.
The number of patients was nearly 6 times larger than in any of the individual studies included in the meta-analysis, he said. More importantly, all patients in the UB/DENT study had their aspirin responder status confirmed, not once, but multiple times. And lastly, he noted it was determined objectively by urinanalysis that all patients were actually taking their prescribed aspirin.
Of the 20 studies included in the BMJ meta-analysis, compliance was confirmed by telephone or interviews in three studies and was not able to be assessed in three more due to insufficient information, according to the report.
In addition to quantifying the prevalence of aspirin resistance and identifying the relationship between aspirin res
|Contact: Lois Baker|
University at Buffalo